CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Loading organization profile…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

Oxford BioMedica (United Kingdom) - Medical Cannabis Research Engine

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Organizations/company

company organization

Oxford BioMedica (United Kingdom)

GB

OPENALEX: I4210146357↗ROR: 03dp0vf82↗

People

Connected researchers

Alex AdamsORCID 0000-0001-9364-8540 Alexandra J. NobleORCID 0000-0002-6894-9672 Dominic OliverORCID 0000-0002-8920-3407 Jack SatsangiORCID 0000-0002-6357-9684 Philip McGuireORCID 0000-0003-4381-0532

Public evidence

3 connected articles

Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMC Prenatal cannabis exposure is associated with alterations in offspring DNA methylation at genes involved in neurodevelopment, across the life course.2025 · Europe PMC Assessing Cannabis Use in People with Psychosis.2024 · Europe PMC

Registered research

Connected studies

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393

Matched by exact identifiers only. Profile data: OpenAlex.